3,397
Views
37
CrossRef citations to date
0
Altmetric
Review

Acinetobacter baumannii Biofilm Formation and Its Role in Disease Pathogenesis: A Review

ORCID Icon, , ORCID Icon, , , ORCID Icon, ORCID Icon & ORCID Icon show all
Pages 3711-3719 | Published online: 10 Sep 2021

References

  • EvansB, HamoudaA, AmyesSGB. The rise of carbapenem-resistant Acinetobacter baumannii. Curr Pharm Des. 2013;19(2):223–238. doi:10.2174/13816121380407028522894617
  • LinMF, LanCY. Antimicrobial resistance in Acinetobacter baumannii: from bench to bedside. World J Clin Cases. 2014;2(12):787–814. doi:10.12998/wjcc.v2.i12.78725516853
  • MulaniMS, KambleEE, KumkarSN, TawreMS, PardesiKR. Tawre MS and pardesi KR. emerging strategies to combat ESKAPE pathogens in the era of antimicrobial resistance: a review. Front Microbiol. 2019;10(539):1–24. doi:10.3389/fmicb.2019.0053930728808
  • Joly-GuillouML. Clinical impact and pathogenicity of Acinetobacter. Clin Microbiol Infect. 2005;11(11):868–873. doi:10.1111/j.1469-0691.2005.01227.x16216100
  • PourNK, DusaneDH, DhakephalkarPK, ZaminFR, ZinjardeSS, ChopadeBA. Biofilm formation by Acinetobacter baumannii strains isolated from urinary tract infection and urinary catheters. FEMS Immunol Med Microbiol. 2011;62(3):328–338. doi:10.1111/j.1574-695X.2011.00818.x21569125
  • LiuA, DuW, XieJ, et al. Role of immunodeficiency in Acinetobacter baumannii associated pneumonia in mice. Chin Med J. 2020;133(18):2161–2169. doi:10.1097/CM9.000000000000102732842019
  • McConnellMJ, ActisL, PachónJ. Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models. FEMS Microbiol Rev. 2013;37(2):130–155. doi:10.1111/j.1574-6976.2012.00344.x22568581
  • FalagasME, RafailidisPI. Attributable mortality of Acinetobacter baumannii: no longer a controversial issue. Critl Care. 2007;11(3):1–3. doi:10.1186/cc5911
  • AntunesLCS, ViscaP, TownerKJ. Acinetobacter baumannii: evolution of a global pathogen. Pathog Dis. 2014;71(3):292–301. doi:10.1111/2049-632X.1212524376225
  • AntunesLCS, ImperiF, CarattoliA, ViscaP. Deciphering the multifactorial nature of Acinetobacter baumannii pathogenicity. PLoS One. 2011;6(8):1–10. doi:10.1371/journal.pone.0022674
  • GordonNC, WarehamDW. Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance. Int J Antimicrob Agents. 2010;35(3):219–226. doi:10.1016/j.ijantimicag.2009.10.02420047818
  • KimYJ, KimSI, KimYR, et al. Carbapenem-resistant Acinetobacter baumannii: diversity of resistant mechanisms and risk factors for infection. Epidemiol Infect. 2012;140(1):137–145. doi:10.1017/S095026881100074421554783
  • YangCH, SuPW, MoiSH, ChuangLY. Biofilm formation in Acinetobacter baumannii: genotype-phenotype correlation. Molecules. 2019;24(10):1–12.
  • RoyR, TiwariM, DonelliG, TiwariV. Strategies for combating bacterial biofilms: a focus on anti-biofilm agents and their mechanisms of action. Virulence. 2018;9(1):522–554. doi:10.1080/21505594.2017.131337228362216
  • AsfawT. Biofilm formation by Enterococcus Faecalis and Enterococcus Faecium: review. Int J Res Stud Biosci. 2019;7(4). doi:10.20431/2349-0365.0704002
  • RunciF, BonchiC, FrangipaniE, VisaggioD, ViscaP. Acinetobacter baumannii biofilm formation in human serum and disruption by gallium. Antimicrob Agents Chemother. 2017;61(1):1–8. doi:10.1128/AAC.01563-16
  • DijkshoornL, NemecA, SeifertH. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol. 2007;5(12):939–951. doi:10.1038/nrmicro178918007677
  • BabapourE, HaddadiA, MirnejadR, AngajiSA, AmirmozafariN. Biofilm formation in clinical isolates of nosocomial Acinetobacter baumannii and its relationship with multidrug resistance. Asian Pac J Trop Biomed. 2016;6(6):528–533. doi:10.1016/j.apjtb.2016.04.006
  • EbrahimiS. Efficacy of isolated bacteriophage against biofilm embedded colistin-resistant Acinetobacter baumannii. Gene Rep. 2021;22:1–11.
  • KrzyściakP, ChmielarczykA, PobiegaM, RomaniszynD, Wójkowska-MachJ. Acinetobacter baumannii isolated from hospital-acquired infection: biofilm production and drug susceptibility. Apmis. 2017;125(11):1017–1026. doi:10.1111/apm.1273928913903
  • Rodríguez-BañoJ, MartíS, SotoS, et al. Biofilm formation in Acinetobacter baumannii: associated features and clinical implications. Clin Microbiol Infect. 2008;14(3):276–278. doi:10.1111/j.1469-0691.2007.01916.x18190568
  • ZeighamiH, ValadkhaniF, ShapouriR, SamadiE, HaghiF. Virulence characteristics of multidrug resistant biofilm forming Acinetobacter baumannii isolated from intensive care unit patients. BMC Infect Dis. 2019;19(1):1–9. doi:10.1186/s12879-019-4272-030606108
  • BalaM, GupteS, AggarwalP, KaurM, ManhasA. Biofilm producing multidrug resistant Acinetobacter species from a tertiary care hospital: a therapeutic challenge. Int J Res Med Sci. 2016;4(7):3024–3026. doi:10.18203/2320-6012.ijrms20161997
  • FajirL, Al-niaameAE, HusseinN. Detection of biofilm formation and its related with aminoglycoside resistance in Acinetobacter baumannii isolates, isolated from some Baghdad City Hospitals. Eur J Biomed Pharm Sci. 2017;4(1):84–91.
  • RaoR, KarthikaR, SinghS, et al. Correlation between biofilm production and multiple drug resistance in imipenem resistant clinical isolates of Acinetobacter baumannii. Indian J Med Microbiol. 2008;26(4):333–337. doi:10.1016/S0255-0857(21)01809-018974485
  • AziziO, ShahcheraghiF, SalimizandH, et al. Molecular analysis and expression of bap gene in biofilm-forming multi-drug-resistant Acinetobacter baumannii. Rep Biochem Mol Biol. 2016;5(1):62–72.28070537
  • BlancoN, HarrisAD, RockC, et al. Risk factors and outcomes associated with multidrug-resistant Acinetobacter baumannii upon intensive care unit admission. Antimicrob Agents Chemother. 2018;62(1):1–7. doi:10.1128/AAC.01631-17
  • ElkhelouiR, LaktibA, MimouniR, et al. Acinetobacter baumannii biofilm: intervening factors, persistence, drug resistance, and strategies of treatment. Mediterr J Infect Microb Antimicrob. 2020;9(7):1–12.
  • EzeEC, CheniaHY, El ZowalatyME. Acinetobacter baumannii biofilms: effects of physicochemical factors, virulence, antibiotic resistance determinants, gene regulation, and future antimicrobial treatments. Infect Drug Resist. 2018;11:2277–2299. doi:10.2147/IDR.S16989430532562
  • JamalM, TasneemU, HusseinTAS. Bacterial biofilm: its composition, formation and role in human infections. Research & reviews. J Microbiol Biotechnol. 2015;4(3):1–14.
  • GarrettTR, BhakooM, ZhangZ. Bacterial adhesion and biofilms on surfaces. Prog Nat Sci. 2008;18(9):1049–1056. doi:10.1016/j.pnsc.2008.04.001
  • JamalM, AhmadW, AndleebS, et al. Bacterial biofilm and associated infections. J Chin Med Assoc. 2018;81(1):7–11. doi:10.1016/j.jcma.2017.07.01229042186
  • StewartPS, FranklinMJ. Physiological heterogeneity in biofilms. Nat Rev Microbiol. 2008;6(3):199–210. doi:10.1038/nrmicro183818264116
  • HannanS, ReadyD, JasniAS, RogersM, PrattenJ, RobertsAP. Transfer of antibiotic resistance by transformation with eDNA within oral biofilms. FEMS Immunol Med Microbiol. 2010;59(3):345–349. doi:10.1111/j.1574-695X.2010.00661.x20337719
  • ParsekMR, SinghPK. Bacterial biofilms: an emerging link to disease pathogenesis. Annu Rev Microbiol. 2003;57:677–701. doi:10.1146/annurev.micro.57.030502.09072014527295
  • Bekele ST, Abay GK, Gelaw B TB. Bacterial Biofilms ; Links to Pathogenesis and Résistance Mechanism. 2018;1–25. doi:10.20944/preprints201807.0598.v1
  • GreeneC, VadlamudiG, NewtonD, FoxmanB, XiC. The influence of biofilm formation and multidrug resistance on environmental survival of clinical and environmental isolates of Acinetobacter baumannii. Am J Infect Control. 2016;44(5):65–71. doi:10.1016/j.ajic.2015.12.012
  • RichardsAM, Abu KwaikY, LamontRJ. Code blue: Acinetobacter baumannii, a nosocomial pathogen with a role in the oral cavity. Mol Oral Microbiol. 2015;30(1):2–15. doi:10.1111/omi.1207225052812
  • CerqueiraGM, PelegAY. Insights into Acinetobacter baumannii pathogenicity. IUBMB Life. 2011;63(12):1055–1060. doi:10.1002/iub.53321989983
  • SatoY, UnnoY, KawakamiS, UbagaiT, OnoY. Virulence characteristics of Acinetobacter baumannii clinical isolates vary with the expression levels of omps. J Med Microbiol. 2017;66(2):203–212. doi:10.1099/jmm.0.00039427902395
  • GaddyJA, ActisLA. Regulation of Acinetobacter baumannii biofilm formation Jennifer. Future Microbiol. 2009;4(1):273–278. doi:10.2217/fmb.09.519327114
  • GaddyJA, TomarasAP, ActisLA. The Acinetobacter baumannii 19606 ompa protein plays a role in biofilm formation on abiotic surfaces and in the interaction of this pathogen with eukaryotic cells. Infect Immun. 2009;77(8):3150–3160. doi:10.1128/IAI.00096-0919470746
  • ChoiCH, LeeJS, LeeYC, ParkTI, LeeJC. Acinetobacter baumannii invades epithelial cells and outer membrane protein A mediates interactions with epithelial cells. BMC Microbiol. 2008;8(1):1–11. doi:10.1186/1471-2180-8-21618173832
  • ChoiCH, LeeEY, LeeYC, et al. Outer membrane protein 38 of Acinetobacter baumannii localizes to the mitochondria and induces apoptosis of epithelial cells. Cell Microbiol. 2005;7(8):1127–1138. doi:10.1111/j.1462-5822.2005.00538.x16008580
  • ChoiCH, HyunSH, LeeJY, et al. Acinetobacter baumannii outer membrane protein A targets the nucleus and induces cytotoxicity. Cell Microbiol. 2008;10(2):309–319.17760880
  • LoehfelmTW, LukeNR, CampagnariAA. Identification and characterization of an Acinetobacter baumannii biofilm-associated protein. J Bacteriol. 2008;190(3):1036–1044. doi:10.1128/JB.01416-0718024522
  • BollJM, TuckerAT, KleinDR, et al. Reinforcing lipid A acylation on the cell surface of Acinetobacter baumannii promotes cationic antimicrobial peptide resistance and desiccation survival. mBio. 2015;6(3):1–11. doi:10.1128/mBio.00478-15
  • LukeNR, SauberanSL, RussoTA, et al. Identification and characterization of a glycosyltransferase involved in Acinetobacter baumannii lipopolysaccharide core biosynthesis identification and characterization of a glycosyltransferase involved in Acinetobacter baumannii lipopolysaccharide core. Infect Immun. 2010;78(5):2017–2023. doi:10.1128/IAI.00016-1020194587
  • RussoTA, MacdonaldU, BeananJM, et al. Penicillin-binding protein 7/8 contributes to the survival of Acinetobacter baumannii in vitro and in vivo. Infect Immun. 2009;199:513–521.
  • JinJS, KwonS, MoonDC, et al. Acinetobacter baumannii secretes cytotoxic outer membrane protein A via outer membrane vesicles. PLoS One. 2011;6(2):1–9. doi:10.1371/journal.pone.0017027
  • RumboC, FernaE, MerinoM, et al. Horizontal transfer of the OXA-24 carbapenemase gene via outer membrane vesicles: a new mechanism of dissemination of carbapenem resistance genes in Acinetobacter baumannii. Antimicrob Agents Chemother. 2011;55(7):3084–3090. doi:10.1128/AAC.00929-1021518847
  • JacobsAC, HoodI, BoydKL, et al. Inactivation of phospholipase D diminishes Acinetobacter baumannii pathogenesis. Infect Immun. 2010;78(5):1952–1962. doi:10.1128/IAI.00889-0920194595
  • GaddyJA, ArivettBA, McconnellMJ, López-rojasR, PachónJ, ActisLA. Role of acinetobactin-mediated iron acquisition functions in the interaction of Acinetobacter baumannii strain ATCC 19606 T with human lung epithelial cells, Galleria mellonella caterpillars, and mice. Infect Immun. 2012;80:1015–1024. doi:10.1128/IAI.06279-1122232188
  • MiharaK, TanabeT, YamakawaY, et al. Identification and transcriptional organization of a gene cluster involved in biosynthesis and transport of acinetobactin, a siderophore produced by Acinetobacter baumannii ATCC 19606 T. Microbiology. 2004;150:2587–2597. doi:10.1099/mic.0.27141-015289555
  • GeisingerE, IsbergRR, WeissD. Antibiotic modulation of capsular exopolysaccharide and virulence in Acinetobacter baumannii. PLoS Pathog. 2015;11(2):1–28. doi:10.1371/journal.ppat.1004691
  • FiesterSE, ArivettBA, SchmidtRE, et al. Iron-Regulated phospholipase C activity contributes to the cytolytic activity and virulence of Acinetobacter baumannii. PLoS One. 2016;11(11):1–26. doi:10.1371/journal.pone.0167068
  • CamarenaL, BrunoV, EuskirchenG, PoggioS, SnyderM. Molecular mechanisms of ethanol-induced pathogenesis revealed by RNA-sequencing. PLoS Pathog. 2010;6(4):1–15. doi:10.1371/journal.ppat.1000834
  • ChoiAHK, SlamtiL, AvciFY, PierGB, Maira-LitranT. The pgaABCD locus of Acinetobacter baumannii encodes the production of Poly-β-1-6-N-acetylglucosamine, which is critical for biofilm formation. J Bacteriol. 2009;191(19):5953–5963. doi:10.1128/JB.00647-0919633088
  • TomarasAP, FlaglerMJ, DorseyCW, GaddyJA, ActisLA. Characterization of a two-component regulatory system from Acinetobacter baumannii that controls biofilm formation and cellular morphology. Microbiology. 2008;154:3398–3409. doi:10.1099/mic.0.2008/019471-018957593
  • NiuC, ClemmerKM, BonomoRA, RatherPN. Isolation and characterization of an autoinducer synthase from Acinetobacter baumannii. J Bacteriol. 2008;190(9):3386–3392. doi:10.1128/JB.01929-0718281398
  • TomarasAP, DorseyCW, EdelmannRE, ActisLA. Attachment to and biofilm formation on abiotic surfaces by Acinetobacter baumannii: involvement of a novel chaperone-usher pili assembly system. Microbiology. 2003;149:3473–3484. doi:10.1099/mic.0.26541-014663080
  • Amala ReenaAA, SubramaniyanA, KanungoR. Biofilm formation as a virulence factor of Acinetobacter baumannii: an emerging pathogen in critical care units. J Curr Res Sci Med. 2017;3(2):74. doi:10.4103/jcrsm.jcrsm_66_17
  • Princy ChoudharySS. Microbial biofilms. Encycl Microbiol. 2019;1–14. doi:10.5772/intechopen.90790
  • ToyofukuM, InabaT, KiyokawaT, ObanaN, YawataY, NomuraN. Environmental factors that shape biofilm formation. Biosci Biotechnol Biochem. 2016;80(1):7–12. doi:10.1080/09168451.2015.105870126103134
  • SindhuS. Clinical significance, antibiotic resistance and biofilm formation of Acinetobacter baumannii. Rev Clin Microbiol. 2018;7(4):1–2.
  • BadaveGK, DhananjayK. Biofilm producing multidrug resistant Acinetobacter baumannii: an emerging challenge. JCDR. 2015;9(1):9–11.
  • Rodrigues PerezLR. Acinetobacter baumannii displays inverse relationship between meropenem resistance and biofilm production. J Chemother. 2015;27(1):13–15. doi:10.1179/1973947813Y.000000015924621167
  • MadananA, KumariS, RoutrayA, YadavD. Imipenem resistance and biofilm production in Acinetobacter. Drug Invent Today. 2013;5(3):256–258. doi:10.1016/j.dit.2013.04.005
  • HøibyN, CiofuO, JohansenHK, et al. The clinical impact of bacterial biofilms. Int J Oral Sci. 2011;3:55–65. doi:10.4248/IJOS1102621485309
  • DiazPM. Impact of biofilm infection and its treatment impact of biofilm infection and its treatment. Int J Adv Microbiol Microbiol Res. 2017;1(1):7–13.
  • WuH, MoserC, WangH, HøibyN, SongZ. Strategies for combating bacterial biofilm infections. Int J Oral Sci. 2014;7:1–7. doi:10.1038/ijos.2014.65
  • SubhadraB, KimDH, WooK, SurendranS, ChoiCH. Control of biofilm formation in healthcare: recent advances exploiting quorum-sensing interference strategies and multidrug efflux pump inhibitors. Materials. 2018;11(9):1–20. doi:10.3390/ma11091676
  • IvankovićT, Goić-BarišićI, HrenovićJ. Reduced susceptibility to disinfectants of Acinetobacter baumannii biofilms on glass and ceramic. Arh Hig Rada Toksikol. 2017;68(2):99–108. doi:10.1515/aiht-2017-68-294630500776
  • NarayananA, NairMS, KarumathilDP, BaskaranSA, VenkitanarayananK, AmalaradjouMAR. Inactivation of Acinetobacter baumannii biofilms on polystyrene, stainless steel, and urinary catheters by octenidine dihydrochloride. Front Microbiol. 2016;7:1–9. doi:10.3389/fmicb.2016.0084726834723
  • MohamedSH, SalemD, AzmyM, FamNS. Antibacterial and antibiofilm activity of cinnamaldehyde against carbapenem-resistant Acinetobacter baumannii in Egypt: in vitro study. J Appl Pharm Sci. 2018;8(11):151–156.
  • Laal-KargarN, DolatabadiS, MohtashamiM. Antibacterial and antibiofilm effects of synbiotics against multidrug-resistant bacteria: Acinetobacter baumannii and Enterococcus faecalis; 2020. 1–26.
  • Shahed-Al-MahmudMD, LinNT. Prevention and degradation of Acinetobacter baumannii biofilm formation by phage ɸAB6 and its tail fiber protein. Virol Mycol. 2018;07:36.